With its data, people, and analytics solutions, SUAZIO provides market insights to the global medical technology sector
NAMSA has acquired Belgium-based SUAZIO, a consultancy that caters to medical device and In vitro diagnostics (IVDs) developers with global market research services.
The financial terms of the deal were not disclosed.
Established in 2001, SUAZIO provides market insights to the global medical technology sector using its data, people, and analytics solutions.
With the acquisition, the US-based NAMSA, now has 20 facilities across the Americas, Europe, and Asia.
Additionally, the deal will help the medical technology contract research organisation (CRO) to expand its presence in market intelligence and customer research services.
SUAZIO is said to create tailored frameworks for its clients based on their specific market requirements, technology value drivers, digital healthcare environments, patient journeys, and financial value propositions.
The research generates data, precise interpretation, and clear suggestions and plans for effective market introductions while considering the perspective of all stakeholders, said NAMSA.
NAMSA CEO Christophe Berthoux said: “NAMSA is very enthusiastic to expand its global strategic consulting services with the addition of SUAZIO.
“Client insights and precise market research are what power the true value of novel medical technologies and product acceptance.
“With the SUAZIO Team, NAMSA will expand its client reach even further and strengthen the delivery of its full continuum development services to the global MedTech industry.”
The American CRO offers other consulting services like biological safety, quality, regulatory, reimbursement and strategy for product development. Its consultants are said to provide consulting services across the product development journey.
SUAZIO CEO Christophe Van der Linden said: “SUAZIO has sought to extend its reach within the MedTech ecosystem for some time and we could not be more thrilled to join NAMSA in its mission to deliver best-in-class global MedTech solutions through our people, expertise and technology.
“With similar values and experience in providing insights to accelerate MedTech innovation, our services are well-aligned to truly deliver global Clients end-to-end development and commercialisation solutions that lead to success.”
In March 2021, NAMSA acquired Minnesota-based American Preclinical Services (APS).